-
Phase 4
-
-
18+Altersgruppe
-
Active, Not Recruiting
Menü
Vielen Dank, dass Sie Ihre Frage übermittelt haben. Sie erhalten innerhalb von zwei Werktagen eine Antwort an die von Ihnen angegebene E-Mail-Adresse. Vielen Dank.
Ein Systemfehler ist aufgetreten. Bitte erneut übermitteln
Active, Not Recruiting
An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice
The purpose of this study is to explore the safety, efficacy, quality of life, and biomarker response in participants with moderate to severe ulcerative colitis in clinical practice.
Inclusion Criteria: - A diagnosis of ulcerative colitis (UC), with signs and symptoms consistent with UC for at least 3 months prior to the first study intervention administration - Moderate to severely active UC disease activity defined as a modified Mayo score of 5 through 9, inclusive - Report of a previous colonoscopy that documents extent of disease Exclusion Criteria: - Current or recent (within 3 months of screening) evidence of fulminant colitis, toxic megacolon, or bowel perforation - Extensive colonic resection or current stoma - Colonic dysplasia that has not been removed Other protocol-defined inclusion/exclusion criteria apply
Studienarme
Experimental: Cohort 1 - Advanced therapy-naive
Studienarme
Experimental: Cohort 2 - Advanced therapy-exposed